Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30